| Cat.No. | Name | Information |
|---|---|---|
| M1766 | PF-04217903 | PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM. |
| M2080 | Capmatinib (INCB28060) | Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. |
| M1765 | Crizotinib (PF-02341066) | Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. |
| M1757 | XL-184 | XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
| M3515 | MK-2461 | MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
| M3396 | NVP-BVU972 | NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. |
| M1922 | MGCD265 | MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3). |
| M1901 | Golvatinib | Golvatinib (E7050) is an orally bioavailable dual kinase inhibitor of c-Met and VEGFR-2 tyrosine kinases with potential antineoplastic activity. |
| M1899 | PHA-665752 | PHA-665752 is a selective small molecule c-MET inhibitor (Ki of 4 nM, IC50 of 9 nM). |
| M1890 | SU11274 | SU11274 is a selective c-Met inhibitor (IC50 = 0.01 μM in vitro). |
| M1811 | Tivantinib (ARQ-197) | Tivantinib (ARQ 197) is a selective and oral small-molecule inhibitor of c-Met with a minimal IC50 value of 0.1 μM. |
| M1793 | JNJ-38877605 | JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met with an IC50 of 4 nM. |
| M1777 | SGX523 | SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. |
| M1758 | Foretinib | Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. |
| M1745 | AMG-458 | AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively. |
| M1683 | BMS 794833 | BMS-794833 is a potent ATP competitive Met/VEGFR-2 kinase inhibitor. |
| M1682 | BMS-777607 | BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. |
| M1647 | AMG-208 | AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM. |
| M54465 | Caveolin-1 (82-101) amide (human, mouse, rat) | Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. |
| M50426 | Norleual | Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. |
| M50210 | Fosgonimeton | Fosgonimeton is a potentially first-in-class Hepatocyte Growth Factor Receptor (HGF) agonist that enhances HGF/MET signaling pathway activity for Alzheimer's Disease (AD) research. |
| M43491 | SU 5616 | SU 5616 is an organic compound. |
| M43490 | MET/PDGFRA-IN-2 | MET/PDGFRA-IN-2 is a MET and PDGFRA protein inhibitor. |
| M43489 | MET/PDGFRA-IN-1 | MET/PDGFRA-IN-1 is a MET and PDGFRA protein inhibitor (IC50: 36 μM for MET). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
